Lymphoma, Malignant
16
1
2
11
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.3%
1 terminated out of 16 trials
91.7%
+5.1% vs benchmark
6%
1 trials in Phase 3/4
36%
4 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (16)
Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim
DS-3201b in Participants With Lymphomas
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma
A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin
Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma
Open-Label, Non Randomized Phase 2 Study With Safety Run-In
Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
Multi-day Doses in Prevention of Nausea and Emesis
Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia